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Background: Alzheimer’s disease (AD) is the most common type of presenile and senile dementia. The human
β-amyloid precursor cleavage enzyme (BACE-1) is a key enzyme responsible for amyloid plaque production, which
implicates the progress and symptoms of AD. Here we assessed the anti-BACE-1 and behavioral activities of
curcuminoids from rhizomes of Curcuma longa (Zingiberaceae), diarylalkyls curcumin (CCN), demethoxycurcumin
(DMCCN), and bisdemethoxycurcumin (BDMCCN) against AD Drosophila melanogaster models.
Methods: Neuro-protective ability of the curcuminoids was assessed using Drosophila melanogaster model
system overexpressing BACE-1 and its substrate APP in compound eyes and entire neurons. Feeding and
climbing activity, lifespan, and morphostructural changes in fly eyes also were evaluated.
Results: BDMCCN has the strongest inhibitory activity toward BACE-1 with 17 μM IC50, which was 20 and 13 times
lower than those of CCN and DMCCN respectively. Overexpression of APP/BACE-1 resulted in the progressive and
measurable defects in morphology of eyes and locomotion. Remarkably, supplementing diet with either 1 mM
BDMCCN or 1 mM CCN rescued APP/BACE1-expressing flies and kept them from developing both morphological
and behavioral defects. Our results suggest that structural characteristics, such as degrees of saturation, types of
carbon skeleton and functional group, and hydrophobicity appear to play a role in determining inhibitory potency
of curcuminoids on BACE-1.
Conclusion: Further studies will warrant possible applications of curcuminoids as therapeutic BACE-1 blockers.
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Alzheimer’s disease (AD) is the most common cause of
presenile and senile dementia in developed and develop-
ing countries [1,2]. The worldwide prevalence of AD was
26.6 million in 2006, and this figure is projected to grow
up to 106.8 million by 2050 [3]. AD is a devastating
neurodegenerative disorder of the brain characterized by
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reproduction in any medium, provided the orwhich are generated by sequential proteolytic processing
of transmembrane amyloid precursor protein (APP) by
two enzymes, β-secretase (β-site APP cleaving enzyme
or BACE-1) and γ-secretase, in the amyloidogenic pro-
cessing pathways [4,5]. Besides acetylcholinesterase
(AChE), BACE-1 is also considered as a key thera-
peutic target for prevention and treatment of AD [6,7].
Transgenic models of AD in Drosophila melanogaster
by driving Aβ production in the central nervous system
and retina of the fly have been developed to gain insight
into mechanism of AD and to illuminate potential thera-
peutic approaches [8-10]. Although many peptides andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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ated as BACE-1 inhibitors [11-13], none of them have
been successfully developed as AD treatment drugs. There
is, therefore, a critical need for the development of new
improved anti-AD agents.
Plant secondary substances have been suggested as po-
tential alternatives for AD therapy largely because plants
constitute a potential source of bioactive chemicals that
have been perceived by the general public as relatively
safe and often act at multiple and novel target sites
[14,15]. These potential new anti-AD products can be
applied to humans in the same manner as conventional
anti-AD drugs. Much effort has been focused on them
as potential sources of commercial anti-AD products for
prevention or treatment of AD. BACE-1 or AChE inhi-
bitors from plants have been well reviewed [13,16] re-
spectively. Recently, plants in the family Zingiberaceae
have drawn attention because they contain anti-AD
principles [17,18]. The rhizomes of turmeric, Curcuma
longa L., are not only important as a spice or flavoring,
but they have also been prescribed for indigestion,
hepatitis, jaundice, diabetes, atherosclerosis and bacter-
ial infection [19-21]. Curcumin, an active ingredient of
C. longa, has been proposed to alleviate Aβ toxicity in
transgenic human Aβ and human tau flies by reducing
the pre-fibrillar/oligomeric species of Aβ [18].
In the current study, an assessment was made of the
BACE-1 inhibitory activity of the three curcuminoid
compounds isolated from C. longa rhizome (curcumin,
demethoxycurcumin, bisdemethoxycurcumin), commer-
cially available curcuminoid compound (tetrahydrocur-
cumin), a natural BACE-1 inhibitor (EGCG) [22], and a
cell-permeable isophthalamide compound (BACE-1 In-
hibitor IV) [23], using a fluorescence resonance energy
transfer (FRET) enzyme assay. The effects of the two
curcuminoids (curcumin and bisdemethoxycurcumin)
on feeding, climbing, and life span as well as morpho-
logical changes in the compound eyes of D. melanogaster
which express human APP and BACE-1 genes within the
developing nervous system and compound eyes were
compared with those of Inhibitor IV. The mode of anti-
AD action and quantitative structure–activity relationship
(QSAR) of the curcuminoids also are discussed.
Methods
Experimental groups
In our experiment, three curcuminoids isolated from
Curcuma longa and one commercial curcuminoid were
tested in vitro. Among these compounds, only two curcu-
minoids, curcumin and bisdemethoxycurcumin, were
tested to flies, because the BACE-1 inhibitory activity of de-
methoxycurcumin in vitro lied between curcumin and bis-
demethoxycurcumin. With this issue, demethoxycurcumin
was removed from the in vivo study. The experimentalgroups tested for in vivo study were illustrated in Figure 1.
GMR-Gal4 drives target human APP and BACE-1 genes
expression in flies’ compound eyes, and morphostruc-
tural changes of these compound eyes with the supple-
mentation of compounds with different concentration
were observed, GMR-Gal4/+ was used as the control
group (Figure 1A), elav-Gal4 drives target genes co-
expression in flies’ nervous system, behaviors including
climbing, life span and feeding assay with the supple-
mentation of compounds with different concentration
were tested, elav-Gla4/+ and elav < BACE-1 were used
as control groups (Figure 1B).
Instrumental analysis
1H and 13C NMR spectra were recorded in CD3CN on a
Bruker AVANCE 600 spectrometer (Karlsruhe, Germany)
using tetramethylsilane as an internal standard, and
chemical shifts were given in δ (ppm). UV spectra were
obtained in MeCN on a Kontron UVICON 933/934
spectrophotometer (Milan, Italy) and mass spectra on a
Jeol JMS-DX 303 spectrometer (Tokyo, Japan). Merck
silica gel (0.063–0.2 mm) (Darmstadt, Germany) was
used for column chromatography. Merck pre-coated sil-
ica gel plates (Kieselgel 60 F254) were used for analytical
thin-layer chromatography (TLC). Merck preparative
thin-layer chromatography plates (2 mm thickness) and
Biotage Isolera one medium-pressure liquid chromatog-
raphy (MPLC) (Uppsala, Sweden) were used for isola-
tion of active principles.
Materials
The four commercially-available pure organic curcumi-
noids examined in this study are listed in Table 1, along
with their sources. For the QSAR analysis, values of mo-
lecular weight (MW), hydrophobic parameter (log P)
and steric effects for the test curcuminoids were ob-
tained from ChemDraw Ultra 10.0 (Cambridge Soft
Corporation, Cambridge, MA) and recorded in Table 1.
Molecular refraction (MR) was used as the parameter for
describing steric effects. Structures of these curcuminoids
are given in Figure 1. EGCG was purchased from Sigma-
Aldrich (St. Louis, MO), Inhibitor IV, and Acid red
were purchased from Merck (Darmstadt, Germany),
and Amresco (Cochran Road Solon, OH), respectively.
Recombinant human BACE-1 and fluorogenic peptide
substrate Mca-SEVNLDAEFRK (Dnp) RR-NH2 were
purchased from R&D system (Minneapolis, MN). All of
the other chemicals and reagents used in this study were
of analytical grade quality and available commercially.
Plants
The rhizomes of C. longa were purchased from Boeun
medicinal herb shop, Kyoungdong market (Seoul, Repub-
lic of Korea (ROK)). A voucher specimen (CL-R1) was
Figure 1 The schematism of experimental fly groups included in our study. GMR-Gal4 drives target human APP and BACE-1 genes expression
in flies’ compound eyes, and morphostructural abservation changes of these compound eyes with the supplementation of compounds with different
concentration, GMR-Gal4/+ as the control group (A), elav-Gal4 drives target genes co-expression in flies’ nervous system, observation behaviors
including climbing, life span and feeding assay with the supplementation of compounds with different concentration, elav-Gla4/+ and elav < BACE-1
used as control groups (B).
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Life Science, College of Agriculture and Life Sciences,
Seoul National University.
Fly stocks
Flies were cultured in a standard cornmeal agar medium
at 25°C and 70% relative humidity (RH) under a 12:12 h
light:dark cycle. Following fly stocks were obtained from
Bloomington Stock Center at Indiana University: w1118Table 1 Values of physical parameters of four
curcuminoids examined in this study
Compound MWa log Pb MRc Sourced
Curcumin 368 2.92 104 S-A
Demethoxycurcumin 338 3.08 98.78 S-A
Bisdemethoxycurcumin 308 3.32 92.10 S-A
Tetrahydrocurcumin 372 2.73 100.63 S-A
aMolecular weight.
bHydrophobic parameter expressed as the log of the octanol/water
partition coefficient.
cParameter for steric effects as described using molecular refraction.
dPurchased from Sigma-Aldrich (St. Louis, MO).(stock number, 3605), UAS-BACE-1, UAS-APP (33797),
UAS-BACE-1 (29877), elav-GAL4 (8760), and GMR-GAL4
(1104). The GAL4/UAS system was employed for the
overexpression of desired genes in a specific tissue of the
fly. The transgenic fly stock UAS-BACE-1 (29877) in our
study was also used in previous study [10]. The character-
izations of trans-human gene APP and BACE-1 flies as a
reliable AD model were presented in results section.Extraction and isolation
The dried rhizomes of C. longa (1.2 kg) was pulverized and
extracted with methanol (3 × 5 L) at room temperature for
2 days and filtered. The combined filtrate was concentrated
under vacuum at 40°C to yield ~105.4 g of a dark yellowish
red tar. The extract (100 g) was sequentially partitioned
into hexane- (31 g), chloroform- (6.55 g), ethyl acetate-
(49 g), butanol- (3.95 g), and water-soluble (9.5 g) portions
for subsequent bioassay. The organic solvent-soluble
portions were concentrated to dryness by rotary evapor-
ation at 40°C and the water-soluble portion was freeze-
dried. For isolation of active principles, 2 mg/ml of each
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enzyme assay as described previously [24].
The chloroform-soluble fraction (5 g) was most active
and MPLC was performed using a Biotage Isolera ap-
paratus equipped with a UV detector at 254 nm and a
column cartridge SNAP (100 g silica gel) with column
volume 132 ml. Separation was achieved with a gradient of
chloroform and methanol [(100:0 (500 ml), 96:4 (1800 ml),
90:10 (400 ml), 80:20 (400 ml) and 0:100 (500 ml) by
volume] at a flow rate 50 ml/min to provide 17 fractions
(each about 180 ml). Column fractions were monitored
by TLC on silica gel plates developed with chloroform
and methanol (95:5 by volume) mobile phase. Fractions
with similar Rf values on the TLC plates were pooled.
Spots were detected by spraying with 2% H2SO4 and
then heating on a hot plate. Fractions 8 to 11 (1.5 g)
were purified by preparative TLC with chloroform and
methanol (95:5 by volume) to yield two active principles
1 (41.7 mg, Rf = 0.47) and 2 (27.2 mg, Rf = 0.42).
The active ethyl acetate-soluble fraction (500 mg) was
chromatographed on a 70 × 1.5 cm silica gel (70 g) column
by elution with a gradient of chloroform and methanol
[(100:0 (250 ml), 99:1 (550 ml), 98:2 (300 ml), 97:3
(300 ml), 96:4 (200 ml), 90:10 (100 ml) and 0:100 (800 ml)
by volume] to afford eight fractions (each about 300 ml).
The active fractions 5 to 6 (34.3 mg) were pooled and
recrystallized in acetone at −20°C to afford an active
principle 3 (13.2 mg).
FRET enzyme assay
The previous method [24] was used with a slight modifica-
tion to assess the BACE-1 inhibitory activity of all com-
pounds. In brief, the assay mixtures containing 1 μl of
0.5 μg/μl recombinant human BACE-1, 0.75 μl of 2.5 μg/
μl fluorogenic peptide substrate, 47.25 μl of 50 mM so-
dium acetate (pH 4.5), and the constituents (0.1–2000 μg/
ml) in 2% dimethyl sulfoxide (DMSO) were preincubated
at 25°C for 1 h followed by adding 16.6 μl of 2.5 M sodium
acetate to stop the reaction. Natural BACE-1 inhibitors
(EGCG) and Inhibitor IV served as standard references
and were similarly prepared. The fluorescence intensity was
measured using a Molecular Devices SpectraMAX Gemini
XS plate reader (Sunnyvale, CA) at 355 nm excitation and
405 nm emission at room temperature. The inhibition per-
centage was calculated with the following equation: % in-
hibition = 100 – [(Fs – Fb)/(Fn – Fb)] × 100, where Fs was
the fluorescence of sample, Fb was the fluorescence of the
mixture of substrate and DMSO without BACE-1 enzyme,
and Fn was the fluorescence of the mixture of BACE-1 en-
zyme, substrate, and DMSO.
Histological analysis
Cason’s trichome staining was performed as described
before [25], In brief, the heads of 5-day-old male flieswere fixed in 4% paraformaldehyde buffer solution (pH,
7.4) at 4°C overnight, after which, paraffin-embedded
preparations of the fly heads were sectioned at 10 μm
thickness by using a HM 340E rotary microtome (Thermo
Scientific Microm, Walldorf, Germany). Sections were
dried at 40°C overnight and subsequently dewaxed with
CitriSolv (Fisher Scientific, Fair Lawn, NJ) and rehydrated
with a series of ethanol to phosphate-buffered saline
solution. Rehydrated paraffin sections were soaked into
Cason’s trichrome stain for 15 min, and slides were
gently swashed in tap water with subsequent wash in
distilled water three times. Excess of water was re-
moved and samples were mounted with mounted with
a Vectorshield H-1000 mounting medium (Vector La-
boratories, Burlingame, CA).
For Congo red staining, sections were dewaxed and then
stained in Congo red solution for 12 min, after which sec-
tions were rinsed in tap water and dehydrated in 50, 70%
ethanol for 1 min, followed by the incubation in 100%
ethanol for 4 min. Slides were dried and mounted with
mounting medium. Images were observed and captured
using EZ4 HD equipped with an Integrated 3.0 Mega-
Pixel CMOS camera (Leica, Heerbrugg, Switzerland).
RT-PCR analysis of human APP and BACE-1 genes in
transgenic fly
Semi-quantitative RT-PCR was performed to assess the
expression levels of human APP and BACE-1 genes in
transgenic fly. Total RNA was extracted from the 30–35
heads of 10-day-old male flies using Trizol (Invitrogen
Corparation, Carlsbad, CA). RNA and primers were sub-
jected to RT-PCR by using AccuPower RT-PCR Premix
(Cat. No. K-2055) (Bioneer, Alameda, CA). This premix
contained optimal concentration of all the components
necessary for cDNA synthesis and RTase inactivation, as
well as amplification in a single 0.2 ml tube. PCR ampli-
fications were performed with specific primers in a total
volume of 20 μl containing 2 μl of forward and reverse
primer mixture (10 pmol of each primer), 1 μg RNA and
DEPC water. The mixture was used for the amplification
after initial denaturation at 95°C and 32 cycles (95°C for
30 s, 60°C for 30 s, and 72°C for 30 s). PCR products
were visualized by 2% agarose gel electrophoresis con-
taining ethidium bromide. The primer sequences were as
follows: for human APP, 5′-GCCGTGGCATTCTTTTG
GGGC-3′(forward) and 5′-GTGGTCAGTCCTCGGTC
GGC-3′ (reverse) [26]; for human BACE-1, 5′-GCAGG
GCTACTACGTGGAGA-3′ (forward) and 5′-GTATCC
ACCAGGATGTTGAGC-3′ (reverse) [27]. RP49, which
encodes the Drosophila ribosomal protein 49, was used
as an internal standard and reference gene using forward
and reverse primer pairs 5′-CTGCTCATGCAGAACC
GCGT-3′ and 5′-GGACCGACAGCTGCTTGGCG-3′
[26], respectively. The ethidium bromide stained gel image
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System (Bio-Rad, Hercules, CA), and calculated by den-
sitometry [28]. Results are presented as relative mRNA
expression of each gene to that of RP49 mRNA.
Light microscopy and scanning electron microscopy of
adult eyes
Flies were cultured from egg stage on 94 × 25 mm poly-
styrene vials containing standard media supplemented
with each test compound as stated previously. Whole
adult flies (1, 24, and 36 days old) were anesthetized in ice
and were put on a microscope slide at room temperature
for light microscopy. Morphostructural observations of
eye were made with a Leica EZ4HD equipped with an In-
tegrated 3.0 Mega-Pixel CMOS camera with 35 ×magnifi-
cation (Hicksville, New York).
For scanning electron microscopy (SEM), ice-anesthe
tized flies (36 days old) were attached to a copper mount
using silver paint as a conducting adhesive. They were
then put directly into the viewing chamber of a scanning
electron microscope without prior coating [29]. The
external surface eye morphology was visualized by a
Carl Zeiss Supra 55VP field-emission scanning elec-
tron microscope (Oberkochen, German) at 15 kV.
Life span assay
Groups of 200 newly eclosed male flies equally distrib-
uted in 10 vials were incubated in media supplemented
with 1 mM CCN, 1 mM BDMCCN, or 200 nM inhibitor
IV in 0.1% DMSO. Controls received 0.1% DMSO only.
Survivors were transferred to fresh media vials every
4 days. The median survival time (T1/2) as the time when
the survivor function equals 50% was determined because
median survivorship reflects a more reliable metric than
the mean survival time [10]. All treatments were repli-
cated 10 times.
Climbing assay
For the climbing activity, we followed procedure de-
scribed previously [9,30]. Flies were collected at eclosion
and cultured in groups of 20 flies in media supple-
mented with 1 mM CCN, 1 mM BDMCCN, or 200 nM
inhibitor IV in 0.1% DMSO. Flies over-expression APP/
BACE-1 were treated with different concentrations (200,
500, and 1000 μM) of curcuminoids, based on our pre-
liminary test results and previous studies [17,31]. Con-
trol flies received media with 0.1% DMSO. Twenty flies
were placed in an empty polystyrene D. melanogaster
vial (95 mm tall × 24 mm diameter) conjoined with other
vial on top and manually banged twice. After 20 s, we
counted flies that climbed and crossed the 9.5 cm line
from the bottom and calculated the climbing index as
the percentage of those relative to the total number of
test flies. All trials were replicated five times.Feeding assay
The adult feeding assay was performed according to pre-
vious study [32] with minor modifications. Flies were
collected at eclosion and aged in groups of 15 males and
15 females with culture media for 3 days, and then
starved for 20 h in vials containing 3 layers of a What-
man no. 2 filter paper (Maidstone, UK) soaked with dis-
tilled water. After starvation, flies were transferred onto
vials containing the media (with 0.2% Acid red) supple-
mented with CCN (200, 500, or 1000 μM), BDMCCN
(200, 500, or 1000 μM), or inhibitor IV (200 nM) in 0.1%
DMSO. Controls were fed with media containing 0.2%
Acid red and 0.1% DMSO. After 2 h of feeding, flies were
anesthetized, and their abdomens were isolated and ho-
mogenized in 1 ml of distilled water. After centrifugation
(5000 rpm, 25°C, 5 min), the optical density (OD) of the
supernatant was measured at 505 nm. The OD values
were as the index of the amount of food taken by flies
[33]. All treatments were replicated three times.
Data analysis
Concentrations of the test compounds causing 50% loss
of BACE-1 (IC50) were calculated using GraphPad Prism
5.1 software (San Diego, CA). The IC50 values for each
D. melanogaster line and their treatments were consid-
ered to be significantly different from one another when
their 95% confidence limits (CL) failed to overlap. All
data are presented as mean ± standard error, and the
significance between means was determined using one-
way or two-way analysis of variance (ANOVA) statistical
test (GraphPad Prism 5.1 software; San Diego, CA). Statis-
tical analysis for survival data were carried out using the
Bonferroni post tests (GraphPad Prism 5.1 software).
Results
FRET bioassay-guided fractionation and isolation of
curcuminoids
Fractions obtained from the solvent hydrolyzable of the
methanol extract of C. longa rhizomes were examined
for inhibitory activity against human BACE-1 using a
FRET-based enzyme assay (Table 2). At a concentration
of 2 mg/ml, both the methanol extract and chloroform-
soluble fractions suppressed completely activity of BACE-1.
At 1 mg/ml, the chloroform-soluble fraction was the
most potent inhibitory material, followed by the ethyl
acetate-soluble fraction. Low and no inhibition were
produced by the butanol- and water-soluble fractions,
respectively. Therefore, the chloroform- and ethyl acetate-
soluble fractions were subjected to further purification
steps to identify inhibitory constituents for BACE-1.
FRET assay-guided fractionation of C. longa rhizome
extract afforded three active principles identified by spec-
troscopic analyses, including MS and NMR. The three
active principles were curcumin (1), demethoxycurcumin
Table 2 BACE-1 inhibitory in vitro activity of fractions
obtained methanol extract of Curcuma longa rhizomes
Material
% inhibition
2 mg/ml 1 mg/ml 0.5 mg/ml
Methanol extract 100 65 57
Hexane-soluble fraction 85 48 43
Chloroform-soluble fraction 100 81 71
Ethyl acetate-soluble fraction 84 76 70
Butanol-soluble fraction 82 26 3
Water-soluble fraction 0 0 0
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(1) was identified on the basis of the following evidence:
brightly yellow colored powder. UV (MeCN): λ max nm
430. EI-MS (70 eV), m/z (relative intensity): 368 [M+]
(100), 350 (67), 272 (23), 231 (24), 217 (25), 191 (48),
190 (60), 177 (93), 145 (26), 137 (44) (Additional file 1:
Figure S1). 1H NMR (CD3CN, 600 MHz): δ 3.31 (6H, s),
5.91 (1H, s), 6.70 (2H, d, J = 15.78), 6.86 (2H, d, J = 8.10),
7.14 (2H, d, J = 8.19), 7.26 (2H, d, J = 1.56), 7.58 (2H, d,
J = 15.78), 9.79 (2H, s), 16.41 (1H, bs) (Additional file 2:
Figure S2). 13C NMR (CD3CN, 600 MHz): δ 56. 8 q, 56.8 q,
102.2 d, 112.1 d, 112.1 d, 116.8 d, 116.8 d, 122. 9 d, 122.9 d,
124.4 s, 124.4 s, 128.7 d, 128.7 d, 142.1 d, 142.1 d, 149.3 s,
149.3 s, 150.5 s, 150.5 s, 206.7 s, 206.7 s (Additional file 3:
Figure S3). Demethoxycurcumin (2): yellow-orange amor-
phous powder. UV (MeCN): λmax nm 430. EI-MS (70 eV),Figure 2 Structures of the curcuminoids. Curcumin (1),
demethoxycurcumin (2), bisdemethoxycurcumin (3), and
tetrahydrocurcumin (4).m/z (relative intensity): 338 [M+] (100), 320 (83), 191 (60),
190 (55), 177 (63), 150 (32), 147 (98), 140 (46), 57 (33)
(Additional file 4: Figure S4). 1H NMR (CD3CN, 600 MHz):
δ 3.31 (3H, s), 5.92 (2H, s), 6.64 (1H, d, J = 15.84), 6.67 (2H,
d, J = 15.84), 6.85 (1H, d, J = 8.40), 6.87 (2H, d, J = 8.64),
7.14 (2H, d, J = 6.48), 7.26 (1H, d, J = 1.74), 7.53 (2H, d, J =
8.64), 7.58 (2H, d, J = 15.84) (Additional file 5: Figure S5).
13C NMR (CD3CN, 600 MHz): δ 56.8 q, 101.8 t, 111.6 d,
116.7 d, 117.3 d, 122.2 d, 122. 4 d, 124.5 d, 128.3 s, 130.6 d,
131.1 d, 131.1 d, 135.2 s, 141.2 d, 141.5 d, 147.1 s, 148.9 s,
158.4 s, 206.3 s, 206.3 s (Additional file 6: Figure S6). Bisde-
methyoxycurcumin (3): yellow crystal. UV (MeCN) λmax
nm 412. EI-MS (70 eV), m/z (relative intensity): 308 [M+]
(52), 290 (33), 202 (20), 161 (30), 160 (44), 147 (100), 120
(23), 119 (25), 107 (31) (Additional file 7: Figure S7). 1H
NMR (CD3CN, 600 MHz): 5.93 (1H, s), 6.81 (4H, d, J =
8.64), 7.48 (4H, d, J = 8.58), 7.56 (4H, d, J = 15.78), 8.90 (2H,
s), 16.40 (1H, bs) (Additional file 8: Figure S8). 13C NMR
(CD3CN, 600 MHz): δ 102.2 t, 117. 3 d, 117.3 d, 117.3 d,
117.3 d,122.6, d, 122.6 d, 128.2 d, 128.2 d, 131.5 d, 131.5 d,
131.5 d, 131.5 d, 142.0 d, 142.0 d, 161.0 s, 161.0 s, 185.1 s,
185.1 s (Additional file 9: Figure S9). The interpretations of
proton and carbon signals of compounds 1, 2, and 3 were
largely consistent with previously described [34].
In vitro BACE-1 inhibitory activity of curcuminoids
The BACE-1 inhibitory activity of all compounds was
likewise compared using in vitro FRET-enzyme assay
(Table 3). Based on IC50 values, BDMCCN was 20 and
13 times more potent at inhibiting BACE-1 than CCN
and DMCCN. The inhibitory activity of DMCCN was
significantly different from that of CCN. THCCN was
ineffective. Overall, these curcuminoids were signifi-
cantly less potent at inhibiting BACE-1 than inhibitor
IV. BDMCCN was significantly more active than EGCG.
Characterization of trans-human APP and BACE-1 genes
fly as a reliable AD model
The GAL4/UAS system was employed for the overex-
pression of desired genes in a specific tissue of the fly. In
our experiment, human APP and BACE-1 genes induced
eye degeneration of transgenic fly under GMR-Gal4
driver strain. Control GMR-Gal4/+ flies showed normalTable 3 Human BACE-1 inhibitory in vitro activity of four
curcuminoids, two phytochemicals and BACE-1 inhibitor IV
Compound IC50, μM (95% CL) Slope ± SE
Curcumin 340 (296–391) 0.7 ± 0.03
Demethoxycurcumin 217 (197–240) 1.0 ± 0.05
Bisdemethoxycurcumin 17 (14–20) 1.9 ± 0.21
Tetrahydrocurcumin > 2000
(−)-Epigallocatechin gallate 82.01(72.59–92.66) 0.9 ± 0.04
BACE-1 inhibitor IV 0.085 (0.075–0.095) 1.2 ± 0.07
Figure 3 Human APP and BACE-1 genes induced eye
degeneration of transgenic fly under GMR-Gal4 driver strain.
Control GMR-Gal4/+ flies showed normal and well-organized
compounds eye (A), this well-organized structure were stained by
Cason’s trichome staining (B) and Congo red staining (C and D).
Transgenic flies GMR < APP/BACE-1 presented rough and irregular
compound eye (E), damages of retina were detected by Cason’s
trichome staining (F) and amyloid depositions were observed in flies’
compound eyes by Congo red staining marked by arrows (G and H).
Scale bar, 50 μm.
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organized structure and normal retina were stained by
Cason’s trichome staining (Figure 3B) and Congo red
staining (Figure 3C and D). However, human APP and
BACE-1 co-expression flies presented rough and irregu-
lar compound eye ( Figure 3E), damages of retina were
showed clearly by Cason’s trichome staining (Figure 3F),
and amyloid depositions were observed by Congo red
staining marked by with arrows (Figure 3G and H). APP
and BACE-1 were expressed in the nervous system under
elav-GAL4 driver strain. We reconfirmed the expression
of APP and BACE-1 genes in the transgenic flies with
semi-quantitative RT-PCR analysis (Figure 4). Target genes
electrophoresis results were observed (Figure 4A), Gene
RP49 was used as the reference gene to normalize mRNA
amount, human APP and BACE-1 genes showed high ex-
pression amount in transgenic fly, however, no expression
in control fly (Figure 4B). In conclusion, trans-human
APP and BACE-1 fly can be used as a reliable AD model.
Effects of curcuminoids on the eye morphology
Morphological defects in flies expressing APP/BACE-1
in compound eye (GMR>Gal4, UAS-APP, UAS-BACE-1
or GMR>APP/BACE-1) were first examined. Control car-
rying GMR-GAL4 alone showed wild-type eye morphology
(Figure 5A). In contrast, GMR>APP/BACE-1 developed
ommatidia atrophia at the edge of compound eye (marked
with star in Figure 5B). Next, we cultured GMR>APP/
BACE-1 flies in media supplemented with 1 mM CCN,
1 mM BDMCCN or 200 nM Inhibitor in 0.1% DMSO
during entire developmental stages. Even on 1 day post-
eclosion, the edge atrophia was already ameliorated in the
flies cultured in CCN- (Figure 5C1) or BDMCCN-media
(Figure 5D1), compared with the vehicle (0.1% DMSO)
control (Figure 5B1). The manifestation of ommatidia
atrophia was also considerably reduced in Inhibitor IV-fed
flies (Figure 5E1). However, any of tested curcuminoids
and Inhibitor IV failed to suppress completely the eye de-
generation phenotype observed in GMR>APP/BACE-1.
Nevertheless, protective effects of CCN, BDMCCN and
Inhibitor IV remained evident in 24 day- and 36-day old
flies (Figure 5).
To compare the protective activities of curcuminoids in
high resolution, we examined compound eyes of GMR>
APP/BACE-1 treated with each compound using scanning
electron microscope (SEM). Control flies (GMR-GAL4/+)
showed smooth appearance of the eye without any defects
of ommatidia size and bristles (Figure 5A4). In contrast,
GMR>APP/BACE-1 flies showed varying degrees of eye
disorganization. The eye of flies treated with the vehicle
showed the strongest phenotypes characterized by absence
of ommatidial bristles and fusion of ommatidia (marked
with arrows) (Figure 5B4). The rough eye phenotype was
suppressed partially in 1 mM CCN-fed flies, but mostommatidial bristles were still absent and the size of
some ommatidia reduced (arrows in Figure 5C4). Re-
markably, protective potency of 1 mM BDMCCN
Figure 4 mRNA expression level of transgenic flies, elav-Gal4/+
as control fly. Target gene human APP and BACE-1 electrophoresis
results (A) and semi-quantitative RT-PCR analysis of human APP and
BACE-1 genes mRNA expression level (B). Gene RP49 was used as
the reference gene to normalize mRNA amount. For RP49 mRNA
expression amount, there was no significant difference between
control flies and transgenic flies, however, mRNA of target genes
human APP and BACE-1 were not expressed in control flies. ns: no
significant difference. Each bar represents standard error.
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tor IV (Figure 5E4).
Effects of curcuminoids on climbing behaviors
Most of neurodegenerative diseases including Alzheimer’s
disease are characterized by age-dependent deterioration
in locomotory coordination. In Drosophila model, the
locomotory coordination can be quantified by the negative
geotaxis assay, which takes advantage of fly’s innate ten-
dency to climb against gravity after gentle tapping. In
the assay, control flies cultured on standard media
(elav-Gal4/+) showed a clear age-dependent reduction
in the climbing indices, for example measured in fe-
males as 98%, 93%, 89% and 66% in 1, 10, 20 and 30 days
after eclosion, respectively (Figure 6A). Further, expression
of BACE-1 with or without its substrate APP in the ner-
vous system resulted in even stronger age-dependent lo-
comotory deterioration in both genders (Figure 6). The
climbing defect was slightly more pronounced in males
than in females, there was virtually no climbing activity
scored in elav > APP/BACE-1 males from 20 days after
eclosion (Figure 6B).
Then, we asked whether two curcuminoids and Inhibi-
tor IV BACE-1 blockers could rescue climbing defects in
males expressing BACE-1 alone (elav > BACE-1) of three
different age groups (10, 20 and 30 days post-eclosion).
In 10 days after eclosion, all tested compounds except1 mM CCN did not significantly improve climbing abil-
ity, probably because overall behavioral defect was not
pronounced in this age group. In contrast, tested 20 and
30 days after eclosion, elav > BACE-1 males cultured in
media containing 1 mM CCN, 1 mM BDMCCN, or 200
nM Inhibitor IV showed significantly improved climbing
indices, compared with those cultured in vehicle control
(0.1% DMSO) media (Figure 7B1-B3).
Subsequently, we carried out analogous experiments
with elav > APP/BACE-1 males, which show much se-
vere age-dependent progression of locomotory defects.
In 10 days post-eclosion, males cultured with CCN (1 mM
only), BDMCCN (200 μM, 500 μM, and 1 mM), or inhibi-
tor IV (200 nM) showed less severe impairments in the
climbing ability compared with flies cultured in vehicle
control (Figure 7C1). In 20 days post-eclosion, virtually
no elav > APP/BACE-1 males can climb against gravity,
due to poor movement coordination. However, dietary
supplement of 1 mM CCN, 1 mM BDMCCN, or 200
nM Inhibitor IV delayed age-dependent progression of
locomotory defects, and improved climbing ability com-
pared with vehicle control (Figure 7C2). The climbing
ability was also partially rescued with 1 mM CCN- and
200 nM Inhibitor IV in 30 days post-eclosion males
(Figure 7C3).
Effects of curcuminoids on life span and feeding
Previously, it was reported that expression of BACE-1
with APP reduced life span of adult flies [10]. Thus, we
asked whether prolonged exposure of elav > BACE-1 or
elav > APP/BACE-1 to curcuminoids increases life span.
The life span of the male flies fed on standard media did
not differ significantly from each other (Figure 8A). Sup-
plementation of 1 mM CCN, 1 mM BDMCCN, and 200
nM inhibitor IV did not affect longevity of elav-Gal4/+
flies (Figure 8B), elav < BACE-1 flies (Figure 8C), and
elav < APP/BACE-1 flies (Figure 8D). Interestingly, cul-
tured in vehicle control, elav > BACE-1 males showed
significantly shorter median life time (T1/2, 33 days) than
control (T1/2, 37 days in elav-Gal4/+). Expression of
APP together with BACE-1 (elav > APP/BACE-1) reduced
T1/2 even further to 30 days (Figure 8E). Culturing flies
in curcuminoids or Inhibitor IV increased T1/2 in elav >
BACE-1 and elav > APP/BACE-1, but not in control
lacking UAS-BACE-1 (elav-Gal4/+). 1 mM BDMCCN
increased T1/2 as much as 200 nM Inhibitor IV did in
elav > BACE-1 flies (42 vs. 41 days). 1 mM BDMCCN
also significantly rescue median life time in elav > APP/
BACE-1 flies (T1/2, 36 days), but 1 mM CCN did not
(Figure 8F).
Because feeding behavior is one of the essential factors
determining longevity of flies and other animals [35], we
examined the effects of compounds on amount of food
intake in adults expressing APP/BACE-1 in the nervous
Figure 5 Rough eye phenotype associated with GMR < APP/BACE-1 Drosophila eye development observed by light microscope and
scanning electron microscope. Light micrographs of GMR < GAL4 flies (A1-A3), GMR < APP/BACE-1 cultured on 0.1% DMSO (B1-B3), 1 mM
curcumin (C1-C3), 1 mM bisdemethoxycurcumin (D1-D3), and 200 nM β-secretase Inhibitor IV (E1-E3). Scanning electron micrographs of day 36
GMR < GAL4 flies (A4) and GMR < APP/BACE-1 cultured on different media (B4-E4). Stars indicate ommatidia atrophia.
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and concentrations examined, CCN, BDMCCN, and In-
hibitor IV did not affect amount of feeding in any of tested
genotypes (Figure 9). This finding indicates that protective
effects of BDMCCN and Inhibitor IV on longevity are not
attributed to their possible anorectic effects.Discussion
Plants and their constituents are a potential for AD ther-
apy because some are selective and biodegrade to nontoxic
products. Various compounds such as alkaloids, phenolics,
and terpenoids, exist in plants and jointly or independ-
ently they contribute to BACE-1 inhibition [6,7]. Human
Figure 6 Climbing behavior of females (A) and males (B) from elav-Gal4/+, elav < BACE-1, and elav < APP/BACE-1 fed standard media.
(n = 50–100 flies ***: p < 0.001, **: p < 0.01, ns: no significant difference). Each bar represents standard error.
Figure 7 Effect of curcumin, bisdemethoxycurcumin, and β-secretase Inhibitor IV supplementation on climbing behavior of 10, 20,
and 30 days old male flies from elav-Gal4/+ (A), elav < BACE-1 (B), and elav < APP/BACE-1 (C) (n = 50–100 flies. (***: p < 0.001, **: p < 0.01,
*: p < 0.05). Each bar represents standard error.
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Figure 8 Effect of curcumin, bisdemethoxycurcumin, and β-secretase Inhibitor IV supplementation on longevity of elav-Gal4/+, elav <
BACE-1, and elav < APP/BACE-1 flies. There was no significant difference in the longevity among three different genotype flies (A). Compound
supplementation did not affect longevity of flies elav-Gal4/+ (B), elav < BACE-1 (C), and elav < APP/BACE-1 (D). Median life time of three genotype
flies cultured on standard medium (n = 200 flies per group. ***: p < 0.001, **: p < 0.01, *: p < 0.05) (E). Median life time of three genotype flies fed on
curcuminoids and BACE-1 Inhibitor IV supplementation media (n = 200 flies per group. **: p < 0.01, *: p < 0.05) (F). Each bar represents standard error.
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(EGCG, (−)-epicatechin gallate) [22]; chromone glycosides
(e.g. aloeresin D) [29]; isoflavones (bavachinin, neocorylin)
and chalcone flavonoids (e.g. bavachromene, bavachal-
cone) [36]; (+)-vitisinol E, (+)-ampelopsin A, and (+)-viti-
sin [37]; furanocoumarins (imperatorin, (+)-byakangelicol)
[38]; amentoflavone-type biflavonoids (e.g. 2,3-dihydroa-
mentoflavone, 2,3-dihydro-6-methylginkgetin) [39]; res-
veratrol and its derivatives [40]. In the current study, the
active principles of C. longa rhizome were determined to
be the diarylalkyls CCN (1), DMCCN (2), and BDMCCN
(3). BDMCCN was the most potent BACE-1 inhibitory
constituent, followed by DMCCN and CCN. Nevertheless,
all of the individual compounds were less inhibitory than
Inhibitor IV.
QSAR of BACE-1 inhibitors have been well reviewed
previously [11,41]. BACE-1 inhibitory activity of 10 cate-
chins and reported that the inhibitory activity seemed to be
related to the pyrogallol moiety on C-2 and/or C-3 catechin
skeleton, whereas the stereochemistry of C-2 and C-3 did
not have the inhibitory activity [42]. In the current study,
absence of methoxy groups in the phenyl rings of CCN
increased the BACE-1 inhibitory activity. In particular,Figure 9 Effect of curcumin, bisdemethoxycurcumin, and β-secretase
elav-Gal4/+, elav < BACE-1, and elav < APP/BACE-1 female (A) and maleabsence of two methoxy groups (BDMCCN) significantly
increased BACE-1 inhibitory activity. However, THCCN
was less potent at inhibiting BACE-1 inhibitory activity
than CCN, indicating that the double bonds appear to be
essential for the enzyme inhibitory activity. This current
finding indicates that structural characteristics, such as de-
grees of saturation, carbon skeleton, types of functional
group, and hydrophobicity rather than MW appear to play
a role in determining the BACE-1 inhibitory activity. Pre-
vious study [42] also reported that BDMCCN exhibited
the most potent inhibitory action on BACE-1 mRNA level,
followed by DMCCN and CCN.
Although multiple pathogenetic factors such as Aβ and
tau aggregation, excessive metal ions, oxidative stress,
acetylcholine level, and increased BACE-1 activity have
been suggested for AD, lifestyles and genetic factors also
are associated with AD development [43]. The potency of
feeding curcumin as a drug candidate to alleviate Aβ tox-
icity in transgenic Drosophila was also studied [18]. They
reported that the longevity and the locomotor activity
of five different AD model genotypes showed up to 75%
improved lifespan and activity for curcumin-fed flies and
any decrease in the amount of Aβ deposition followingInhibitor IV supplementation on adult flies feeding behavior of
(B) flies. n = 45 flies. Each bar represents standard error.
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study, we showed prolonged exposure to either CCN or
BDMCCN could rescue morphological defects observed
in flies expressing APP and BACE-1 in compound eyes
(GMR > APP/BACE-1). In addition, dietary supplement
of CCN or BDMCCN also improved movement coord-
ination significantly in elav > BACE-1 and elav > APP/
BACE-1 flies, but not in control. Lastly, both BDMCCN
and Inhibitor IV increased median life time of elav >
BACE-1 and elav > APP/BACE-1 flies. This finding along
with BACE-1 inhibitory action indicates that materials
derived from C. longa rhizome root may hold promise
for the development of novel and effective anti-AD
products.Conclusions
C. longa rhizome-derived preparations containing curcu-
minoids described could be useful as sources of potential
therapeutics or lead molecules for prevention or treat-
ment of AD. For practical use of C. longa rhizome-
derived materials as novel anti-AD products to proceed,
further research is needed to establish their human safety
and whether this activity could be exerted in vivo after
consumption of the product by humans. Historically, the
rhizome has been commonly used as a spice in curries
and other South Asian and Middle Eastern cuisine, flavor-
ing agents, and coloring agents [44]. In addition, their
anti-AD modes of action need to be established and for-
mulations for improving anti-AD potency and stability
need to be developed because of the poor bioavailability
and stability in solution [18].Additional files
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